MALAT1 Promotes Tumorigenesis and Increases Cellular Sensitivity to Herceptin in HER2-positive Breast Cancer
| Autor: | Cunchuan Wang, Yuehua Li, Hongbo Zhu, Renjie Zhu, Chuansheng Yang, Yeru Tan, Xiaoping Wu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
Carcinogenesis Breast Neoplasms medicine.disease_cause Small hairpin RNA Mice Breast cancer Cell Line Tumor Drug Discovery medicine Animals Humans PTEN skin and connective tissue diseases Cell Proliferation Pharmacology MALAT1 biology Cell growth business.industry Trastuzumab medicine.disease Long non-coding RNA Gene Expression Regulation Neoplastic MicroRNAs Oncology SKBR3 biology.protein Cancer research Female RNA Long Noncoding business |
| Zdroj: | Current Cancer Drug Targets. 21:860-869 |
| ISSN: | 1568-0096 |
| DOI: | 10.2174/1568009621666210618164300 |
| Popis: | Background: The function of MALAT1, a long non-coding RNAs (lncRNA), in HER2- positive breast cancer remains largely unexplored. Objectives: This study aimed to investigate the effect of MALAT1 on tumor development in HER2-positive breast cancer. Methods: We detected MALAT1 expression in HER2-positive breast cancer cells and tissues, and analyzed the effects of MALAT1 on cell proliferation in HER2-positive breast cancer cells lines (BT-474 and SKBR3). A mouse xenograft model was established for detecting the function of MALAT1 in HER2-positive breast cancer. Results & Discussion: As a result, MALAT1 was remarkably up-regulated in HER2-positive breast cancer both in cells and tissues. In addition, the silencing of MALAT1 inhibited the proliferation of HER2-positive breast cancer cells both in vitro and in vivo. Furthermore, knockdown of MALAT1 by shRNA down-regulated DNMT1, DNMT3a, and DNMT3b, while up-regulated BRCA1 and PTEN in HER2-positive breast cancer both in cell lines and mouse xenograft models. Conclusion: In short, MALAT1 might be a potential biomarker and therapeutic target for HER2- positive breast cancer therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|